Navigation Links
Researcher, magnet lab receive $2 million grant to target tuberculosis
Date:1/17/2008

TALLAHASSEE, Fla. -- About 5,000 people around the world die from tuberculosis every day, but no effective new drugs have been developed to combat it in 40 years. Researchers at the National High Magnetic Field Laboratory at Florida State University hope to change that through research made possible by a $2-million grant from the National Institutes of Health.

The award will make it possible for Timothy A. Cross, the Earl Frieden Professor of Chemistry and Biochemistry at FSU, and his team to work toward arming drug developers with a map of the proteins on the bacterias surface that are vital for infection.

Because it isnt often seen in the news in the United States, TB often is overlooked, but it remains one of the globes most deadly infectious diseases. The bacterial infection primarily attacks the lungs, causing 2 million deaths around the world each year. Many of the worlds poor are among its victims, and researchers have raised the alarm about drug-resistant strains of the infection, which, according to the Centers for Disease Control, now account for almost one in five new TB cases.

Some potential new treatments for TB already are being researched, said Cross, who also directs the magnet labs Nuclear Magnetic Resonance program, but there is no knowing if those treatments will survive clinical trials.

Trying to treat so much of the world with the same pharmaceuticals is one of the best ways to develop more resistance to treatment, so its important to come at this from as many angles as possible, he said.

Weve done a preliminary study that shows our work is viable, and we have a lot of preliminary data, Cross said of the research plan, expected to take five years to execute. His team, collaborating with the University of Kansas, the University of Alabama and Case Western Reserve University, will use the magnet labs sophisticated 900 megahertz magnet, as well as other resources, to conduct its research.


'/>"/>
Contact: Timothy A. Cross
cross@magnet.fsu.edu
850-644-0917
Florida State University
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Society of Cardiovascular Magnetic Resonance chooses open access
2. Transcranial magnetic stimulation: An effective treatment for depression
3. Penn research shows transcranial magnetic stimulation effective in treating major depression
4. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
5. A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
6. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
7. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
8. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
9. Novadaqs SPY System receives clearance for use in organ transplant surgery
10. Philadelphia Policeman Helps Amputee Receive Power Wheelchair from The Scooter Store
11. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher, magnet lab receive $2 million grant to target tuberculosis
Researcher, magnet lab receive $2 million grant to target tuberculosis
Breaking Medicine Technology:Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 1Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 2OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 1OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 2OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 3OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 4OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 5Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 1Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 2Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half 58618 3